Would you consider reserving CDK4/6 Inhibitors as second line treatment in patients with advanced HR+ HER2 negative breast cancer given SONIA and PALMIRA trial results?

Will the SONIA trial impact your clinical use of CDK4/6 inhibitors in metastatic breast cancer?

• Yes, will defer CDK4/6i to 2nd line (after prior endocrine monotherapy) in all patients except those with visceral mets or highly symptomatic disease
• Yes, will defer CDK4/6i to 2nd line (after prior endocrine monotherapy) in all patients regardless of sites/symptom burden
• Yes, will defer CDK4/6i to 3rd or later lines (after prior endocrine monotherapy and other targeting agents such as SERD/PI3K/PARP/mTOR)
• No, I will continue using CDK4/6i with 1st line ET for all patients
• No, I will continue using CDK4/6i in 2nd or later lines of therapy
• Other